Last reviewed · How we verify
Longeveron Mesenchymal Stem Cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Longeveron Mesenchymal Stem Cells (Longeveron Mesenchymal Stem Cells) — Longeveron Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Longeveron Mesenchymal Stem Cells TARGET | Longeveron Mesenchymal Stem Cells | Longeveron Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Longeveron Mesenchymal Stem Cells CI watch — RSS
- Longeveron Mesenchymal Stem Cells CI watch — Atom
- Longeveron Mesenchymal Stem Cells CI watch — JSON
- Longeveron Mesenchymal Stem Cells alone — RSS
Cite this brief
Drug Landscape (2026). Longeveron Mesenchymal Stem Cells — Competitive Intelligence Brief. https://druglandscape.com/ci/longeveron-mesenchymal-stem-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab